Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Paying the price for the crap financing which amazingly nobody takes the rap for apart from existing shareholders and the continuing dilution. Dear oh dear, shocking performance as per usual.
Not risky for new investors/traders at this price dv with the Croda deal underpinning future sp rises but has certainly been painful for LTH's who have bought at much higher prices
Yep, very risky investment here with 'background' shenanigans....
Yep, certainly no mystery why the sp suddenly rose to 14.20 on the 28th March enabling Macquarie Bank to claim the price had reached "agreed higher levels" before triggering a further big conversion in March below the lowest sp point 5 trading days before at 7.25p. No doubt arranged for a few shares to be bought in the market, this on 12th Mar "Furthermore, Macquarie Bank/CLG have agreed to no further conversions for the month of March unless price and volumes reach certain agreed higher thresholds.". As I have said previously, I await the Umesh Modi figures before judging whther this level of dilution has been worth it
Another FUDDY shorter
7.58m new shares at 6.59p, this is going lower now.
Toyin, The increase in annual turnover from about £335m should provide investors with insight into the effectiveness of their sales team throughout the organisation. Impressive!
Thomas, you do know when you buy an asset it has to be paid for?
The foot balm has massive potential, for e.g. have you done any research on Modi, latest figures I can find say annual turnover of $550m and they have launched our foot balm in six countries with a sales force of 1200.
If you think sbtx is a joke and Croda will buy it for peanuts, why dont you sell up, even better short it. Let's see how that works out for you!
Foot balm has such huge potential,
Croda will be laughing at this stupidity and will buy this company for peanuts.
The last placing at 19p, what will this placing be at.............?
A placing would be ideal to clear the overhang .
Ideally at 10p
TW mentioning a placing absolutely reeks of him deciding that’s what needs to happen, and then knowing SA will ignore him now he has made a t!t of himself, has started the ball rolling in another way.
For what it’s worth, I actually hope it happens, clears the CLN, maybe even raise something towards the next acquisition which SA says is much smaller, and removes the elastic band from the waist of the share price just in time for Croda news. I’d be quite happy with that. I’d be interested in counter views from other LTH’s though…
Start a rumour and panic, then load up.
Market manipulating shyster - that TW? (only imo of course)
Think your trying too hard...
Just saying......
I didn't see that, oh well timelines always move here.
GLA
Yep, the same TW who failed to pick up on any rumours of an Opti placing and advised people to buy Opti in the mid 20s. He might be right this time or he might be wrong
Bazz, to quote you ..."From the RNS"
The completion of the full study and analysis of the total data set is required to understand the outcomes. Of the 3 cohorts participating, cohorts 1 and 2 will complete by end March 2024, with cohort 3 finalising end April and the final results reported as soon as possible thereafter.
You mean the rumour he started, by saying there was a rumour in his bearcast on the 28th March! Just saying........
Tom W suggests there are rumours abound of another placing coming at around 10p to raise c£1.5 million to pay off remaining amounts and redemption fees of CLG. Just saying..........
GLA
220 people took part over 56 days (8 weeks), interim results 5 weeks released on 27th Feb so maybe took a week to for them to share which suggests the 8 weeks were up around 15th to 20th March. How long does it take to put a spreadsheet together to share the results? Hopefully by end of Qtr1 was said, well that was missed. let's hope they come out tomorrow then!!
GLA
I Have a Dream, a song to sing
To help me cope, with anything
If you see the wonder, of a fairy tale
You can take the future, even if you fail
I believe in angels
Something good in everything I see
I believe in angels
When I know the time is right for me
I'll cross the stream, I Have a Dream
I Have a Dream, a fantasy
To help me through, reality
And my destination, makes it worth the while
Pushin' through the darkness, still another mile
Didn't I would be tempted to post the above and obvious to the thread
But couldn’t help myself lol
mol
PG, You seem to imply that the Company should withhold information to prevent or limit firesale events, as discussed this week. This information would have to be sensitive to prices to have the desired effect, which is, of course, illegal. Regarding the timing of the news, like the upcoming M&A that Aquae hinted at, the board has taken a different approach and is exploring an alternative means to fund the next move. Investors should appreciate this as a clear indication that they are heeding and responding to the concerns expressed by investors and the market. My extensive experience spanning over three decades suggests that such actions are uncommon, and it requires courage from the board to change course, so to speak.
I know it is deeply unnerving to see the SP become so volatile; also frustrating if you do not have the funds to take advantage of the opportunity at hand if you have a 12-month plus horizon. The CBs have created a fabulous opportunity for those unconcerned about the short term and who have faith in the long term, which I guess many of us have.
Ref the trades question; sorry I forgot to answer. I believe there was a pattern with some of the larger trades. They appeared to be match buy/sell sides, which suggested an organised swap. If I am correct, there could be more of the CBs washing through than we know of thus far. Either way, it will be short-lived, especially if SA/MR deliver on their master plan. IMHO, some of the most vicious sceptics will eat large portions of humble pie. The Dermatonics/UMG combo will demonstrate the fiscal nonsense some people argue to be wholly wrong, and the vehicle to acquire was a necessary gamble to secure both. The CB looks bad now, but I genuinely believe SA/MR will be vindicated. I hope they have the option to claw back their pay cut.
Recent Developments
Last Updated: 22/03/2024
SBTX accompanied their half year results on 22 March with an interesting Investor Meet presentation, which can be found on the site, and featuring alongsideCEO Stuart Ashman the CFO, the Sederma (Croda) trials director and the CEO of the recent Dematonics acquisition. Revenues remain low (£107,000 + 38%), but they have signed up a new partner to market their psoriasis product via Amazon. Key points from the RNS and presentation included:
Final clinical trial stage to complete May/June of 5 year work with Sederma- now not binary, but a question of whether they can launch with clinical claims and correspondingly higher price point or not.
Marketing deal for Axisbiotix with World Products via Amazon, who they have got to know through Dermatonics acquisition
Dermatonics has high but as yet unquantified hopes for sales in Asia via the Umesh Modi group.
They are looking at cutting raw material costs.
Will launch an acne product this year. The data for the 220 person study backing this up was released in an RNS in February.
Unwinding CLN arrangement but say they now have potential of alternative funding lines for other acquisitions.
CEO and CFO have taken 20% pay cut after criticism of their pay.
Operating loss was £1.39m vs £1.35m, cash at end December £2.84m vs £1.31m at end June, after a £3.3m gross placing in November.
SBTX announced a new six-month research project (“Epidem”) at Manchester University on 18 March, which they are co-funding, to look at the use of non-pathogenic bacteria in wound healing. It will be run by two professors. At the same time they announced that their (Manchester-based) CSO, Professor Cath O’Neill, is stepping back from her role to “return to academia” but will remain as a Scientific adviser.
mol
By another
Investment Case
SkinBioTherapeutics is potentially well positioned to be a leader in the skin health probiotic market. The company has two active developments arms: SkinBiotix is a partnership with Croda in developing new anti-ageing products (the collaboration contract was extended for 12 months in October). AxisBiotix is a food supplement to treat psoriasis sufferers which was introduced to the market through a pilot launch both in the UK and the USA in November 2022. The company is targeting significant markets with its lead opportunities but so far has not yet made material progress, so positive consumer reviews are encouraging. As well as psoriasis and cosmetics applications, SBTX has in the past referred to other potential applications for their formulations, including wound care (Medbiotix), oral health and acne – where progress on the patient study has now been reported.
The Direct-to-Consumer launch of AxisBiotix in late 2021 did not initially generate the hoped-for sales in the UK and the company acknowledged that it needed to change its marketing strategy and is looking for a global distributor. Launches in Europe are being done directly by the company. The timing of progress with Croda is very reliant on Croda’s internal processes. SBTX remains a very small company tackling very large categories and success would be transformative but is dependent on take-up by larger companies.
Brokers Cavendish has June 2024 forecasts of £1.1m revenues (so a big ramp up from H1, but starting to show the benefit of Dermatonics), £2.4m loss at EBITDA level and net debt of £600,000. For the next year the key will be for when and to what extent royalties start flowing from the Croda relationship. Cavendish revised its numbers after the Dermatonics announcement to a target of 48p, slightly down taking into account the new convertible note. As things stand this seems very distant and the company will need to provide clarity on future funding, as well as meeting the now heightened expectations of a launch with Croda.